IDH1 is considered as a marker of secondary GBM and those primary GBMs diagnosed with IDH1 mutations may have been secondary gliomas that rapidly progressed to GBM with no early low-grade clinical symptoms experienced by patients [29]. This evidence concerns the gene IDH1 and glioma.